首页> 外文OA文献 >PCN33 Indirect Analysis of the Efficacy and Safety of Pemetrexed/Cisplatin Compared With Bevacizumab/Gemcitabine/Cisplatin as First-Line Treatment for Advanced, Non-Squamous Non-Small Cell Lung Cancer and Associated Treatment Costs in the Private Mexican Health Care System

【2h】

PCN33 Indirect Analysis of the Efficacy and Safety of Pemetrexed/Cisplatin Compared With Bevacizumab/Gemcitabine/Cisplatin as First-Line Treatment for Advanced, Non-Squamous Non-Small Cell Lung Cancer and Associated Treatment Costs in the Private Mexican Health Care System

机译：培美曲塞/顺铂与贝伐单抗/吉西他滨/顺铂相比作为晚期，非鳞状非小细胞肺癌一线治疗的有效性和安全性的PCN33间接分析及墨西哥私人医疗保健系统中的相关治疗费用

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Ramirez Gamez J.; Cruz Cadena A.; Davey P.; Rajan N.; Barraclough H.; Orlando M.;
展开▼
作者单位

展开▼
年度 2012
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. An indirect comparison of bevacizumab plus cisplatin-gemcitabine and cisplatin plus pemetrexed treatment for patients with advanced first-line non-squamous non-small cell lung cancer in East Asia. [J] . Chang JW, Thongprasert S, Wright E, Asia-Pacific journal of clinical oncology . 2011,第Suppla2期

机译：贝伐单抗联合顺铂-吉西他滨与顺铂联合培美曲塞治疗间接比较东亚地区晚期一线非鳞状非小细胞肺癌患者。
2. An indirect comparison of bevacizumab plus cisplatin-gemcitabine and cisplatin plus pemetrexed treatment for patients with advanced first-line non-squamous non-small cell lung cancer in East Asia. [J] . Chang JW, Thongprasert S, Wright E, Asia-Pacific journal of clinical oncology . 2011,第Suppla2期

机译：贝伐单抗联合顺铂-吉西他滨与顺铂联合培美曲塞治疗间接比较东亚地区晚期一线非鳞状非小细胞肺癌患者。
3. An indirect comparison of bevacizumab plus cisplatin-gemcitabine and cisplatin plus pemetrexed treatment for patients with advanced first-line non-squamous non-small cell lung cancer in East Asia [J] . John Wen-Cheng CHANG, Sumitra THONGPRASERT, Elaine WRIGHT, Asia-Pacific Journal of Clinical Oncology . 2011,第s2期

机译：贝伐单抗联合顺铂-吉西他滨和顺铂联合培美曲塞治疗东亚晚期一线非鳞状非小细胞肺癌患者的间接比较
4. Predictive factors of the treatment outcome in patients with advanced biliary tract cancer receiving gemcitabine plus cisplatin as first-line chemotherapy [D] . 鈴木, 裕子 2019

机译：吉西他滨联合顺铂一线化疗对晚期胆道癌患者治疗效果的预测因素
5. A randomized phase 2 study comparing pemetrexed plus best supportive care versus best supportive care as maintenance therapy after first-line treatment with pemetrexed and cisplatin for advanced non-squamous non-small cell lung cancer [O] . Nabil Mubarak, Rabab Gaafar, Samir Shehata, 2012

机译：一项随机2期研究比较了培美曲塞加顺铂联合一线治疗晚期非鳞状非小细胞肺癌的培美曲塞加最佳支持治疗与最佳支持治疗作为维持治疗
6. Efficacy and Safety of Cisplatin/Pemetrexed Versus Cisplatin/Gemcitabine as First-Line Treatment in East Asian Patients with Advanced Non-small Cell Lung Cancer: Results of an Exploratory Subgroup Analysis of a Phase III Trial [O] . Chih-Hsin Yang, Lorinda Simms, Keunchil Park, 2010

机译：顺铂/聚氯胺蛋白/芽蛋白/吉西他滨的疗效和安全性是东亚患者先进的非小细胞肺癌的一线治疗：III期试验的探索性亚组分析的结果

PCN33 Indirect Analysis of the Efficacy and Safety of Pemetrexed/Cisplatin Compared With Bevacizumab/Gemcitabine/Cisplatin as First-Line Treatment for Advanced, Non-Squamous Non-Small Cell Lung Cancer and Associated Treatment Costs in the Private Mexican Health Care System

著录项

引文网络

相似文献

相关主题

期刊订阅